Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 12

Expert Insights: Investigational ADCs Safety Profiles

September 25, 2024

Hope Rugo, MD, Aditya Bardia, MD, MPH, FASCO

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Overview of Current ADCs in Breast Cancer

EP. 2: ADCs in Breast Cancer: Mechanism of Action, and Components

EP. 3: Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

EP. 4: Expert Perspectives on the Management of SG-Related Neutropenia

EP. 5: Navigating SG-related Diarrhea

EP. 6: Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP. 7: Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP. 8: Clinical Management Considerations: Pneumonitis associated with T-DXd

EP. 9: Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP. 10: Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP. 11: Future Perspectives on ADCs in Breast Cancer

Now Viewing

EP. 12: Expert Insights: Investigational ADCs Safety Profiles

EP. 13: Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

While these agents are still investigational, and their safety profiles have not been officially established…
Can you comment on any pertinent treatment-related adverse effects (TRAEs) associated with patritumab deruxtecan (HER3-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies?
Please comment on any pertinent TRAEs associated with datopotamab deruxtecan (Dato-DXd) reported in these clinical trials that the community oncologists should be aware of and your respective management strategies.